Exclusion criteria:
- Patients with metastatic involvement of any region,
- Patients with any other malignancy.
Nineteen patients who were planned to be treated with BCG for high-grade NMIBC between February 2016 and November 2017 and 19 healthy participants for comparison were enrolled in the study. Healthy participants were selected randomly, and urinary ultrasonography and urinary analyses were performed to exclude bladder malignancies.